mycoBiologics is an Aberdeen biotechnology company developing antibody-based treatments for serious fungal infections. It is a University of Aberdeen spinout, and its website lists a base at the university's Institute of Medical Sciences.
The company uses patient-derived human monoclonal antibodies to create a new class of antifungal therapy, aimed first at critical Candida infections in hospitalised patients. This work is built on a proprietary platform it calls FungoBiologic. Earlier plans also covered hospital-acquired Gram-negative bacterial infections that resist antibiotics. The company says it is now part of the INCATE portfolio.
Dr Fiona Rudkin leads the business as chief executive. She received a Wellcome Innovator Award for the fungal antibody programmes. The project was awarded £400,000 from Scottish Enterprise's High Growth Spinout Programme and took part in Opportunity North East's life sciences accelerator. mycoBiologics Ltd was incorporated in February 2024 and won £85,000 at Scottish EDGE Round 26.
Related news
We Offer
This business has not added this information yet. Claim this profile to request access and add what your business offers.
We're Looking For
This business has not added this information yet. Claim this profile to request access and tell other Scottish businesses what you are looking for.
Location
University of Aberdeen, Institute of Medical Sciences, Aberdeen, AB25 2ZD
